Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Silica 12CH for Silicosis Symptoms
NCT06011785Phase 1Not yet recruiting
- Sponsor
- HOHM Foundation
- Start
- Mar 2024
- Primary completion
- Mar 2025
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 1, open-label trial of colloidal silicon dioxide in silicosis (2 arms), sponsored by HOHM Foundation. Primary endpoint: Measure Yourself Concerns and Wellbeing Symptoms 1 and 2 at 1 year. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
colloidal silicon dioxide
03
Conditions
silicosis
Beyond the preview
Go deeper on NCT06011785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06011785.